The signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held

On April 8, 2024, the signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held in Beijing between Excyte Biopharma Ltd. (hereinafter referred to as "EXCYTE") and Beijing Highthink Pharmaceutical Technology Service Co., Ltd. (hereinafter referred to as " Highthink ", stock code: 873896). Chairman Meng Qingwu and President Yuan Qing'an of EXCYTE, Chairman and President Qi Xuebing of Highthink attended the ceremony.

In the presence of leaders and guests, EXCYTE and Highthink have successfully executed the agreement, marking a new phase in clinical research for YK012. They will collaborate to drive forward the project, explore enhanced treatment, and ultimately benefit patients.